US2022296632A1PendingUtilityA1
Mrna functionalization method
Est. expiryDec 27, 2036(~10.4 yrs left)· nominal 20-yr term from priority
A61K 48/005A61K 31/7115A61P 33/00A61K 47/6911A61K 2039/53A61K 47/549A61K 48/00A61K 2039/6025A61P 31/10A61K 47/50C12N 15/117A61K 31/7088A61K 39/0001A61K 39/39A61K 39/0003A61P 37/04A61P 35/00A61P 31/04A61P 31/12A61K 39/0011A61K 2039/5154A61K 39/00A61K 31/713A61K 48/0008Y02A50/30
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a functionalized mRNA including mRNA and double-stranded RNA including at least one RNA oligomer hybridized with mRNA. Functionalized mRNA is provided according to this configuration.
Claims
exact text as granted — not AI-modified1 . A method for stabilizing a carrier, which comprises:
allowing a carrier to load therein an mRNA encoding a target gene and at least one RNA oligomer hybridizing with the mRNA, wherein the RNA oligomer comprises: (a) an RNA sequence consisting of a sequence of 12 to 40 nucleotides complementary to the sequence of the mRNA, or (b) an RNA sequence having an identity of 90% or more to a sequence of 12 to 40 nucleotides complementary to the sequence of the mRNA, and hybridizing with the mRNA, and the RNA oligomer is chemically unmodified or is chemically modified.
2 . The method of claim 1 , wherein the RNA sequence consists of a sequence of 15 to 23 nucleotides.
3 . The method of claim 1 , wherein the RNA sequence consists of a sequence of 17 nucleotides.
4 . The method of claim 1 , wherein the RNA oligomer comprises said RNA sequence (a) or (b) that is chemically modified.
5 . The method of claim 4 , wherein the chemical modification is performed on the 5′-terminus or 3′-terminus of the sequence of the RNA oligomer via an overhang sequence consisting of 1 to 5 nucleotides.
6 . The method of claim 5 , wherein the overhang sequence is a sequence consisting of 2 nucleotides.
7 . The method of claim 4 , wherein the chemical modification is modification with a hydrophobic group.
8 . The method of claim 4 , wherein the modification with a hydrophobic group is cholesterol modification.
9 . The method of claim 4 , wherein the chemical modification is polyethylene glycol modification.
10 . The method of claim 1 , wherein the carrier is a polymeric micelle or a lipidic mRNA carrier.Join the waitlist — get patent alerts
Track US2022296632A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.